NCT03538301: A trial that was reported late by Nitto Denko Corporation
This trial has reported, although it was 40 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03538301 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 18, 2018 |
| Completion date | Aug. 24, 2022 |
| Required reporting date | Aug. 24, 2023, midnight |
| Actual reporting date | Oct. 3, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 40 |